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Background: Critical commentaries suggest that wound care randomised controlled trials (RCTs) are often poorly
reported with many methodological flaws. Furthermore, interventions in chronic wounds, rather than being drugs,
are often medical devices for which there are no requirements for RCTs to bring products to market. RCTs in
wounds trials therefore potentially represent a form of marketing. This study presents a methodological overview of
chronic wound trials published between 2004 and 2011 and investigates the influence of industry funding on
methodological quality.
Methods: A systematic search for RCTs for the treatment of chronic wounds published in the English language
between 2004 and 2011 (inclusive) in the Cochrane Wounds Group Specialised Register of Trials was carried out.
Data were extracted on aspects of trial design, conduct and quality including sample size, duration of follow-up,
specification of a primary outcome, use of surrogate outcomes, and risks of bias. In addition, the prevalence of
industry funding was assessed and its influence on the above aspects of trial design, conduct and quality was
assessed.
Results: A total of 167 RCTs met our inclusion criteria. We found chronic wound trials often have short durations of
follow-up (median 12 weeks), small sample sizes (median 63), fail to define a primary outcome in 41% of cases, and
those that do define a primary outcome, use surrogate measures of healing in 40% of cases. Only 40% of trials used
appropriate methods of randomisation, 25% concealed allocation and 34% blinded outcome assessors. Of the
included trials, 41% were wholly or partially funded by industry, 33% declared non-commercial funding and 26%
did not report a funding source. Industry funding was not statistically significantly associated with any measure of
methodological quality, though this analysis was probably underpowered.
Conclusions: This overview confirms concerns raised about the methodological quality of RCTs in wound care and
illustrates that greater efforts must be made to follow international standards for conducting and reporting RCTs.
There is currently minimal evidence of an influence of industry funding on methodological quality although
analyses had limited power and funding source was not reported for a quarter of studies.
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Chronic wounds, of which venous leg ulcers, pressure
ulcers and foot ulcers make up the majority [1], are
prevalent conditions that have considerable impact on
patients’ quality of life and are costly to treat. For
example, venous leg ulcers are estimated to affect 15 to
18 in 1,000 people in the United Kingdom (UK) and cost
between £300 and £600 million (UK pounds) per year in
health expenditure [2]. Despite the clinical and financial
significance of chronic wounds, a number of commenta-
tors have expressed concerns about both the quantity
and quality of RCTs within the broader area of wounds
research [3-5].
RCTs within the field of chronic wounds, as within all
areas of medicine, represent an essential part of this evi-
dence base due to their ability to provide unbiased esti-
mates of relative treatment effects. However, the generation
of such unbiased estimates depends on adequate methodo-
logical measures being taken to minimise bias. For example,
it has been demonstrated that failure to conceal allocation
and failure to blind outcome assessors and participants
results in biased, larger estimated effect sizes [6-12]. The
failure to specify a primary outcome a priori can also
introduce bias as authors are free to cherry pick out-
comes for reporting that show a statistically significant
difference [13]. As well as methodological features of
RCTs that can minimise bias, other elements of study de-
sign also impact the overall quality of evidence generated.
These design features include sample size, choice of pri-
mary outcome and the duration of post-randomisation
follow-up. Trial sample size is important because while
estimates from small trials are not necessarily biased,
they will be under-powered to detect anything but the
largest treatment effects, which also leads to small trials
being associated with publication bias [14]. The choice of
primary outcome is similarly important and needs to be
meaningful to both clinicians and patients. Duration of
follow-up is linked to issues of study power and outcome
selection. Important outcomes such as wound healing
can take a long time to achieve (often months for chronic
wounds). Studies with a short duration of follow-up will
potentially miss outcome events and be underpowered.
One approach is the selection of other surrogate out-
comes that can be measured over a shorter period but
which may not be valid proxies for, or may be harder to
interpret than, clinically meaningful outcomes.
The importance of methodological characteristics, such
as those outlined above, has led to a number of studies
being conducted that sought to quantify the methodo-
logical quality on both samples of RCTs from across
medicine [15,16] and within specific areas [17-20]. How-
ever, despite the methodological concerns described
above, no such overview exists within the area of chronic
wounds - an area of medicine where most treatments aremedical devices for which RCT data are not necessary for
licensing and marketing.
Previous research in other areas of medicine suggests
that funding can have an important impact on a number
of trial characteristics. For example, studies have observed
that industry-funded drug trials are more likely to report
in favour of (the sponsored) treatment when compared
with research not funded by a commercial organisation
[21-24]. Studies have also shown commercial funding to
be associated with shorter duration of follow-up, [25]
more frequent use of non-active comparators [26,27] and
a tendency to be at a lower risk of bias [24,28-30]. In the
area of chronic wounds, there is little data regarding the
prevalence of industry-funded trials or the influence of
industry funding on trial design. This study is a methodo-
logical review of recent trial evidence in the field of
chronic wounds. It aims to assess the prevalence of
industry-funded trials in chronic wound care and identify
whether funding source is associated with features of
methodological quality.
Methods
This study was protocol-driven with all search terms,
selection criteria and analysis pre-specified.
Selection
A library of eligible RCTs in chronic wound care was
assembled and used. Eligible studies were:
1. Randomised comparisons of treatments for foot, leg
or pressure ulcers in any setting and for any
category of patient (studies that included other
wound types as well were excluded)
2. Published between 2004 and 2011 (inclusive)
3. Reported in English (due to a lack of translation
resources)
Studies were excluded if they were:
1. Secondary reports, where the primary report of the
main study was referenced
2. Conference abstracts (since these typically do not
contain sufficient methodological information in
order to assess risk of bias (RoB)
3. A protocol of a trial
4. A cost effectiveness study (unless they also reported
the effectiveness of an intervention)
5. A phase 1 trial (since these are not aimed at
determining effectiveness)
Trials were considered to be a RCT and included if
they were described as ‘randomised’ either in the title or
in the text of the paper. If no randomisation process was
referred to, the study was excluded.
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Wounds Group Specialised Register of Trials. The Register
is maintained by the Cochrane Wounds Group and aims
to identify all randomised and quasi-randomised controlled
trials in the area of wounds research. Reports are identified
for inclusion in the register by regular searches of a num-
ber of databases including Medline, Embase, CINAHL and
Central along with periodic searches of other databases.
Studies included in the register have been coded on several
criteria including wound type. A search was therefore car-
ried out using the following search terms in the condition
field: Pressure* or Venous or Leg* or Ulcer* or Diabet*,
and intervention field: Treat*.
The titles and abstracts (where available) of the identi-
fied studies were screened by a single author to exclude
studies which obviously did not meet the inclusion
criteria. The full text was obtained for the all studies that
were potentially relevant. Two authors independently
checked the full papers for eligibility. Any disagreements
were resolved through discussion, and where agreement
could not be reached, a third author acted as arbitrator.
Data extraction
For each eligible study relevant data were initially ex-
tracted by one of seven authors. A second independent
extraction was completed by a single author (blinded to
the initial extraction). Any disagreements were resolved
through discussion. Where agreement could not be
reached, a third author arbitrated. The process of data
extraction was extensively piloted with data recorded on
a Microsoft Access database (Microsoft, Redmond, WA,
USA - http://office.microsoft.com/en-gb/access/), using
drop-down menus where possible.
Data extracted included the publishing journal, impact
factor of publishing journal, journal specialty, wound type,
study design (parallel or other), number of randomisedTable 1 Definitions used in assessment
Primary outcome Primary or main outcomes defined exp
described explicitly in primary study ob
Type of outcome Primary outcomes where defined were
healed or time to complete healing; su
outcome; and, non-healing if the prima
or pain.
Sequence generation Method described for generating the r
including computer-generated sequen
Allocation concealment Method described to prevent the indiv
predicting the allocation sequence in a
numbered envelopes
Blinding of assessors Outcome assessors had no knowledge
and the outcome measurement was u
Overall risk - Low risk of bias: Study was at low risk
- Unclear risk of bias: Study at unclear r
- High risk of bias: Study was at high rigroups, sample size, duration of follow-up, funding
source, primary outcome if defined, and information on
the interventions and comparators investigated (further
information on decision rules for data classification can
be found in Additional file 1). Risk of bias was assessed
using the Cochrane risk of bias tool [31,32] for the do-
mains sequence generation, allocation concealment and
blinding of outcome assessors. An overall assessment risk
of bias was also made following Cochrane guidelines [32].
See Table 1 for definitions used in assessments.
Data analysis
Descriptive summary statistics were calculated for each
of the general and methodological items specified, and
outcomes were stratified by wound type and by funding
source. The descriptive summary statistics were then
used to compare the methodological quality of commer-
cially funded and non-commercially funded randomised
trials for which mean differences or odds ratios (OR) (as
appropriate) with 95% confidence intervals (CI) were cal-
culated. To assess difference in study duration between
studies with different funding sources, mean differences
were logged. Results were initially recorded in Microsoft
Access (Microsoft, Redmond, WA, USA - http://office.
microsoft.com/en-gb/access/) and Stata 12 (StataCorp,
College Station, TX, USA – www.stata.com) was used for
data analysis.
Results
The results of the study selection process and reasons for
exclusion are presented in Figure 1. We identified 647
potentially eligible studies. After an initial assessment of
titles and abstracts, 385 studies were excluded and full
text copies of the remaining 262 potentially eligible stud-
ies were obtained. Ninety-five were excluded for the fol-
lowing reasons: 36 concerned an ineligible wound type;licitly, or an outcome used in power calculation, or a main outcome
jectives
classified as complete healing if primary outcome was proportion
rrogate healing if the primary outcome was any other healing-related
ry outcome was a non-healing outcome such as presence of infection
andomisation sequence used to allocate participants to study groups,
ces, random number tables, and coin tosses
idual responsible for enrolling trial participants from knowing or
dvance, including central randomisation or sealed, opaque, sequentially
of the participants’ group allocation or it was judged that the outcome
nlikely to be influenced by lack of blinding (for example, mortality).
of bias in all three domains.
isk of bias in one or more domain and at high risk of bias in none.
sk of bias in one or more domains.
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cate publications of existing studies; 23 were secondary
reports of included studies; 1 paper was not in English; 2
were trial protocols; and 4 studies were excluded due to
exceptionally poor reporting, which made judgement of
whether the study met the inclusion criteria impossible.
The remaining 167 studies met the inclusion criteria.
Table 2 presents the general characteristics of the 167
included studies stratified by wound type. Leg ulcers were
the most frequently investigated of the three wound types
(38%; 63/167), closely followed by foot ulcers (34%; 57/
167). Only 19% (31/167) of trials focused on pressure ul-
cers over the eight-year period investigated. A further
9.6% (16/167) of trials investigated more than one wound
type.
The majority of trials were parallel in design (96%;
160/167), with only 4.2% (7/167) using other trial designs
(either crossover or factorial). Most (parallel) trials had
just two intervention arms (90%; 144/160); 8.8% (14/
160) had three arms, and 1.3% (2/160) had four arms.
The most frequent intervention types investigated
were dressings and topical agents (25%; 42/167), drugs
(20%; 33/167), growth factors (9.6%; 16/167), bandages
and stockings (8.4%; 14/167), and tissue grafts (6.6%;Figure 1 Overview of review process.11/167). There were a further 23 different technologies
investigated.
The majority of trials were reported in specialty journals
(93%; 156/167), with 34% (57/167) published in wounds
journals. The remaining studies (7.0%, 11/167) were pub-
lished in general medical journals. Of the included studies,
77% (128/167) were published in a journal with an ISI im-
pact factor. The median impact factor for the 128 studies
was 1.93, (interquartile range (IQR 1.21 to 3.01)).
In total, 35% (58/167) of studies were reported as
having been commercially funded, 33% (55/167) were not
commercially funded, and 6.0% (10/167) had funding
from both commercial and noncommercial sources. The
remaining 26% (44/167) of studies either did not report
the source of funding, or the status of the funding source
was unclear.
Table 3 presents information on a number of methodo-
logical characteristics of the included trials. The median
number of participants was 60 (IQR 35 to 99), with a me-
dian of 28 (IQR 16 to 48) participants per treatment arm.
The median duration of follow-up of the trials was 12
weeks (IQR 6.7 to 24) and varied significantly depending
on the nature of the primary outcome. Studies reporting
surrogate measures of healing (for example, change in
Table 2 General characteristics of included studies
All (n = 167) Leg ulcers (n = 63) Pressure ulcers (n = 31) Foot ulcers (n = 57)
Journal type
General medical 11 (6.6%) 3 (4.8%) 4 (13%) 2 (3.5%)
Wounds specialty 57 (34%) 26 (41%) 10 (32%) 13 (23%)
Non-wounds specialty 99 (59%) 34 (54%) 17 (55%) 42 (74%)
Impact factor
Median (IQ range) 1.93 (1.21 to 3.01) 2.38 (1.26 to 3.21) 1.63 (1.36 to 2.48) 1.48 (0.799 to 2.90)
Funding
Commercial 58 (35%) 24 (38%) 7 (23%) 16 (28%)
Mixed 10 (6.0%) 3 (4.8%) 2 (6.5%) 5 (8.8%)
Non-commercial 55 (33%) 20 (32%) 14 (45%) 16 (28%)
Unclear/not reported 44 (26%) 16 (25%) 8 (26%) 20 (35%)
Study design
Other
Parallel 160 (96%) 58 (92%) 30 (97%) 56 (98%)
7 (4.2%) 5 (7.9%) 1 (3.2%) 1 (1.8%)
Study groupsa
2 144 (90%) 52 (90%) 27(90%) 51 (91%)
3 14 (8.8%) 6 (10%) 2 (6.7%) 4 (7.0%)
4+ 2 (1.3%) 0 (0.0%) 1 (3.3%) 1 (1.8%)
Intervention
Bandages/stockings 14 (8.4%) 14 (22%) 0 (0.0%) 0 (0.0%)
Dressings/topical Agents 42 (25%) 20 (32%) 10 (32%) 10 (18%)
Drugs 33 (20%) 8 (13%) 4 (13%) 16 (28%)
Growth factors 16 (9.6%) 0 (0.0%) 0 (0.0%) 13 (23%)
Tissue grafts 11 (6.6%) 4 (6.3%) 1 (3.2%) 5 (8.8%)
Other 51 (31%) 17 (27%) 16(52%) 13(23%)
Comparators
Placebo 50 (30%) 14 (22%) 12 (39%) 18 (32%)
Usual/standard Care 43 (26%) 20 (32%) 8 (26%) 12 (21%)
Named comparison 74 (44%) 29 (46%) 11 (35%) 27 (47%)
aParallel trials only.
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to 15.9) compared with 24 weeks (IQR 12.9 to 26.1) for
studies with a primary outcome of either time to complete
healing or proportion of wounds completely healed.
The proportion of trials that defined a primary out-
come measure was 59% (98/167). Of those that defined
a primary outcome, 41% (40/98) reported a measure of
complete healing as the primary outcome (either time
to complete healing or proportion of wounds com-
pletely healed), 48% (47/98) reported an intermediate
(surrogate) measure of healing (for example, change
in ulcer size/area) and 11% (11/98) of trials reported a
primary outcome that was unrelated to healing (for
example, pain).The Cochrane risk of bias assessment [30,31] revealed
that of the 167 included trials, only 40% (67/167) de-
scribed an appropriate method of random sequence
generation; 59% (98/167) were unclear or did not report
the method of sequence generation and 1.2% (2/167) re-
ported using inappropriate methods of sequence gener-
ation such as alternation or date of birth. Only 25% (41/
167) of trials reported adequate methods of allocation
concealment, such as remote telephone randomisation
or sealed, opaque, sequentially numbered envelopes; 74%
of (123/167) trials were unclear or did not report their
method of allocation concealment; and 1.8% (3/167) did
not adequately conceal allocation. With regards to blind-
ing of outcome assessors, 34% (56/167) of trials were
Table 3 Methodological characteristics of included studies
All (n = 167) Leg ulcers (n = 63) Pressure ulcers (n = 31) Foot ulcers (n = 57)
Number of participants(median (IQ range))
Overall 60 (35 to 99) 81 (43 to 126) 44 (26 to 60) 50 (30 to 86)
Per treatment arm 28 (16 to 47) 37 (21 to 62) 21 (7 to 30) 27 (15 to 43)
Duration(in months; median (IQ range))
All 2.8 (1.6 to 5.6) 3.0 (2.8 to 6.0) 1.9 (0.9 to 3.3) 3.0 (1.4 to 4.7)
PO: Complete healing 5.6 (3.0 to 6.1) 6 (3.0 to 12) 3.9 (1.3 to 6) 4.7 (4.7 to 5.6)
PO: Surrogate healing 2.8 (1.7 to 3.7) 2.8 (1.9 to 3.0) 1.6 (0.93 to 2.8) 1.9 (1.1 to 3.4)
PO: Nonhealing 1.7 (1.4 to 2.1) 1.9 (1.6 to 36) 1.4 (1.4 to 1.4) 1.9 (1.4 to 3.9)
PO: Not defined 2.8 (1.3 to 4.3) 3 (1.6 to 5.6) 1.8 (0.85 to 3.0) 2.8 (0.93 to 3.7)
Primary outcome
Complete Healing 40 (24%) 18 (29%) 4 (13%) 16 (28%)
Surrogate Healing 47 (28%) 15 (24%) 14 (45%) 12 (21%)
Non-healing 11 (6.6%) 3 (4.8%) 1 (3.2%) 6 (11%)
None 69 (41%) 27 (43%) 12 (39%) 23 (40%)
Sequence generation
Low RoB 67 (40%) 27 (43%) 15 (48%) 19 (33%)
Unclear RoB 98 (59%) 36 (57% 15 (48%) 37 (65%)
High RoB 2 (1.2%) 0 (0.0)% 1 (3.2%) 1 (1.6%)
Allocation concealment
Low RoB 41 (25%) 22 (35%) 5 (16%) 11 (19%)
Unclear RoB 123 (74%) 41 (65%) 24 (77%) 45 (80%)
High RoB 3 (1.8%) 0 (0.0%) 2 (6.5%) 1 (1.6%)
Blinding of assessors
Low RoB 56 (34%) 13 (21%) 15 (48%) 23 (40%)
Unclear RoB 64 (38%) 24 (38%) 13 (42%) 22 (39%)
High RoB 47 (28%) 26 (41%) 3 (9.7%) 12 (21%)
Overall RoB
Low RoB 10 (6.0%) 4 (6.3%) 2 (6.5%) 3 (5.3%)
Unclear RoB 107 (64%) 33 (52%) 24 (77%) 41 (72%)
High RoB 50 (30%) 26 (41%) 5 (16%) 13 (23%)
PO, primary outcome; RoB, risk of bias.
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clear risk and 28% (47/167) of trials were at high risk of
bias. Following Cochrane review guidelines [31] to con-
struct an overall risk of bias assessment, 30% (50/167) of
trials were judged to be at high risk of bias, 64% (107/
167) at unclear risk of bias and just 6.0% (10/167) at low
risk of bias.
Table 4 presents the methodological characteristics of
the included studies stratified by funding source. The
sample sizes of commercially funded trials were not
statistically significantly different from those of non-
commercially funded trials (difference 8.0 participants,
95% CI −25 to 41). Differences in duration were mod-
elled using a log model due to the data being highlyskewed. There was no statistically significant difference
in the duration of follow-up between commercially
funded and non-commercially funded trials (with com-
mercially funded studies having, on average −1.3 months,
less follow-up , 95% CI −1.8 to 1.06 months). Commer-
cially funded trials were not more or less likely to specify
a primary outcome than non-commercially funded trials
(OR 1.48, 95% CI .74 to 2.94), and were no more likely
to identify a surrogate healing measure as their primary
outcome (OR 0.68, 95% CI 0.29 to 1.57). There was no
statistically significant difference between commercially
funded and non-commercially funded trials in the likeli-
hood of being classified as at either high or unclear risk of
bias in the domains of sequence generation (OR 0.63, 0.34
Table 4 Methodological characteristics of included studies by funding type








Overall 63 (40 to 117) 52 (28 to 91) 60 (29 to 98)
Per treatment arm 30 (18 to 51) 26 (14 to 44) 23 (14 to 41)
Duration (in months; median
(IQ range))
Overall 2.8 (1.9 to 5.6) 3.0 (1.9 to 6.0) 2.0 (1.2 to 3.5)
Primary outcome
Complete healing 17 (25%) 15 (27%) 8 (18%)
Surrogate healing 26 (38%) 11 (20%) 10 (23%)
Non-healing 5 (7.4) 4 (7.3%) 2 (4.5%)
None 20 (29%) 25 (45%) 24 (55%)
Sequence generation
Low RoB 23 (34%) 31 (56%) 14 (32%)
Unclear RoB 43 (63%) 24 (44%) 30 (68%)
High RoB 2 (2.9%) 0 (0.0)% 0 (0.0%)
Allocation concealment
Low RoB 21 (31%) 13 (24%) 7 (16%)
Unclear RoB 45 (66%) 41 (75%) 37 (84%)
High RoB 2 (2.9%) 1 (1.8%) 0 (0.0%)
Blinding of assessors
Low RoB 23 (34%) 23 (42%) 10 (23%)
Unclear RoB 19 (28%) 20 (36%) 25 (57%)
High RoB 26 (38%) 12 (22%) 9 (20%)
Overall RoB
Low RoB 3 (4.4%) 5 (9.1%) 2 (4.5%)
Unclear RoB 37 (54%) 37 (67%) 33 (75%)
High RoB 28 (41%) 13 (24%) 9 (20%)
RoB, risk of bias.
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0.62 to 1.88) or blinding of outcome assessors (OR 0.84,
95% CI 0.47 to 1.50). There was no statistically significant
difference between industry-funded and nonindustry-
funded trials in the odds of being classified as at high or
unclear risk of bias overall (OR 0.91, 95% CI 0.54 to 1.52).
Discussion
Key findings
This study aimed to describe a number of methodological
characteristics of trials in chronic wounds published during
the period from 2004 to 2011 and identify whether funding
source was associated with the methodological quality of
trials. Trial reports in chronic wounds tend to be published
in comparatively low impact journals with a significant
proportion of studies being published in journals with no
published impact factor.The average sample size observed in our sample of trials
was very small. The statistical power of a hypothetical trial
involving 60 participants (the median sample size), where
approximately 50% of ulcers heal in 12 weeks [32] (the
median duration of follow-up) and where it is assumed
there is a modest effect size of 15% [32], would be just
21%. In other words, only one in five of the trials in our
sample are sufficiently large to detect a statistically signifi-
cant treatment effect should one exist. The vast majority
of chronic wounds trials are therefore underpowered to
detect all but very large effects. While there is some
debate regarding the importance of adequately powering a
trial to detect a difference, [33-35], there is evidence that
published small trials yield larger effect sizes than large tri-
als [14], most likely as a result of publication bias. The fact
that many chronic wounds trials are small means that
it is very important that systematic reviewers check for
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that authors register trials so that reviewers can identify
on-going and potentially unpublished material.
Whilst many trials specified a primary outcome, a
significant proportion did not. There were opportunities
for authors to cherry pick results (that is, presenting out-
comes for which their statistically significant differ-
ences). In a related study, Lockyer et al. [36] found that
86% of wound trials that did not define a primary out-
come claimed a significant treatment effect. This raises
deep suspicion of bias given the inadequate statistical
power of trials in this field.
Our results show that the use of surrogate healing mea-
sures (for example, change in ulcer size) is widespread
and indeed the majority of studies that define a primary
outcome use these intermediate measures of healing. The
cost of longer term follow-up is likely to be the primary
reason for this. Clearly such cost reductions represent an
advantage of utilising surrogate outcomes, and there is
good evidence that a number of surrogate endpoints such
as initial change in ulcer size are good predictors for the
clinically meaningful endpoint of complete healing
[37-39]. There are, however, a number of reasons to re-
main cautious about using surrogate endpoints. Firstly,
surrogate measure of healing such as change in ulcer size
or area introduce the complex issue of how to measure
ulcer size and opens the potential for inaccuracies and
lack of reliability in systems of measurement. A recent
systematic review into the performance of instruments
for the measurement of pressure ulcers revealed little
evidence to support the reliability of different methods of
measurement, particularly with regard to ulcer depth and
volume [40]. Secondly, while some studies have shown
surrogate healing measures to be good predictors of
complete healing, what is less clear is their ability to dif-
ferentiate between treatment effects. It is not enough that
a surrogate predicts the clinical endpoint, it must also be
able to predict changes in the clinical endpoint due to
different treatment effects [41,42].
The results of the risk of bias assessments raise a num-
ber of concerns. Across all three bias domains, a minority
of trials were at low risk of bias. Assessment of bias was,
however, hindered by poor reporting with the vast major-
ity of studies at unclear risk for at least one domain.
While it is encouraging that only a small minority of
studies were at high risk of bias for either sequence
generation or allocation concealment, it is impossible to
make any judgement about the prevalence of high risk of
bias trials in these domains when such a large proportion
of trials are poorly reported. Previous research has sug-
gested that reporting is worse than conduct [43,44] and
perhaps the majority of studies are at low risk of bias,
however the previous studies [43,44] were conducted in
highly regulated fields and it would be inappropriate togeneralise to the area of chronic wounds trials. Even
under the most optimistic scenario (that the unclear risk
trials reflect poor reporting rather poor trial method-
ology) there remains a substantial risk of bias in chronic
wounds trials due to almost a third of trials not blinding
outcome assessors.
The methodological quality of commercially funded trials
and non-commercially funded trials was not significantly
different across all the included measures of methodo-
logical quality. Based on current evidence it is not possible
to draw the conclusion regarding the influence of funding
source on the methodological quality of chronic wounds
trials, although we acknowledge the limited power in these
analyses that in turn also limits the conclusions that can be
drawn. Furthermore, the overall standard of trial quality
was very poor and wound trialists share a culture that
international trial design, conduct and reporting standards
do not seem to have penetrated. Almost a quarter of the
sample had an unclear funding source; more transparency
in declaring support for research will allow more studies to
be included in future analysis of this type.Comparison with other studies
Our results are very similar to those obtained in other
methodological reviews that used samples of trials from
across medicine (for example, Hopewell et al. [16]).
Chronic wounds trials are therefore not considerably
methodologically weaker than trials conducted in some
other areas of medicine. The cohort assessed in Hopewell
et al. [16], however, was much older and dated back to
2000 and this study includes trials up to 2011, thus limiting
comparability, particularly as the impact of CONSORT
may mean that trials are now of higher methodological
quality than observed by Hopewell et al. [16]. It should
also be noted that the methodological quality of reports
assessed by Hopewell et al. [16] was poor and the fact that
chronic wounds trials may be of comparable quality is no
reason for complacency or celebration.Limitations
The initial selection of studies was carried out by a sin-
gle reviewer and lack of translation services means that
only English language papers were included. As a result
our sample may not be fully representative of all the
chronic wounds trials published during the period 2004
to 2011. While it is difficult to predict how inclusion of
non-English language studies would have impacted the
findings, evidence from other fields suggest that meth-
odological quality is similar or slightly higher in English
language publications, compared with those published in
other language [45-48]. On this basis, our results would
represent a conservative assessment of methodological
quality of chronic wounds trials.
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only on information contained within trial reports and
does not necessarily mean poor trial conduct. Studies
[43,44] have compared the content of published reports
with their protocol and found that the methodological
techniques in the actual trial were of better quality than
reported in the final publication. However, these focused
on specific areas of medicine, and as such, the results
may not be generalizable to a chronic wounds context.
Assessment of review protocols and contacting trialists
for more information may have revealed that the trials
were of better quality than reported in the final publica-
tion. This was not done in this study.
Conclusions
This methodological review of recent chronic wounds
trials presents a profile of the recent trial literature in this
area. It identifies that chronic wounds trials tend to suffer
from a number of methodological deficiencies, with trials
tending to be small and underpowered, with short
follow-up periods, widespread use of surrogate healing
measures and frequently no primary outcome specified.
Further, on the basis of Cochrane review guidelines, a
significant proportion of trials would be considered to be
at either unclear or at high risk of bias.
The fact that such a large proportion of the trial evi-
dence base is methodologically weak inevitably has a huge
impact on the potential for current chronic wounds trials
to inform practice. Given the considerable expense of con-
ducting RCTs and the ethical implications of recruiting
participants to methodologically weak studies, much
greater efforts must be made by researchers to ensure that
best practice is followed wherever possible. In particu-
lar, much greater efforts must be made to blind out-
come assessors [49]. While there are occasions where
blinding of assessors is not possible, it is important to
emphasise that blinding is possible in wounds trials as
has been demonstrated in a number of studies, often
by using photographic assessment by masked adjudica-
tors [33,50,51].
While funding source was not associated with greater
risk of bias, the unfortunate reality is that, with few excep-
tions, chronic wounds trials are unacceptably poor across
a whole range of measures of methodological quality. In
the light of these findings the publication of methodo-
logical guidelines for comparative effectiveness research in
chronic wounds by the Centre for Medical Technology
Policy represents a positive step in improving the meth-
odological quality of chronic wounds trials [52]. Moving
forward, it is incumbent upon all stakeholders in chronic
wounds research, irrespective of funding source, to insist
on the improvements and recommendations outlined in
these guidelines. If improvements are not made, there will
continue to be a deficit in high quality evidence availableto inform practitioners’ decisions regarding the best treat-
ment options for their patients.
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